Myriad Genetics annual gross margin
2022
2023
2024
2025
Myriad Genetics's gross margin was 69.93% for fiscal 2025.
View full Myriad Genetics company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 69.93% | +0.04 pp |
| 2024 | 2024-12-31 | 69.89% | +1.25 pp |
| 2023 | 2023-12-31 | 68.64% | −1.58 pp |
| 2022 | 2022-12-31 | 70.22% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 66.60% | −4.64 pp |
| Q1 2026 | 2026-03-31 | 68.66% | +0.16 pp |
| Q4 2025 | 2025-12-31 | 69.97% | −1.68 pp |
| Q3 2025 | 2025-09-30 | 69.91% | −0.32 pp |
| Q2 2025 | 2025-06-30 | 71.23% | +1.68 pp |
| Q1 2025 | 2025-03-31 | 68.50% | +0.45 pp |
| Q4 2024 | 2024-12-31 | 71.65% | — |
| Q3 2024 | 2024-09-30 | 70.23% | — |
| Q2 2024 | 2024-06-30 | 69.55% | — |
| Q1 2024 | 2024-03-31 | 68.05% | — |
Across the available reported history, Myriad Genetics's gross margin increased from 69.89% to 69.93%, a change of +0.04 percentage points. The latest reported quarter, Q2 2026, shows 66.60%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Myriad Genetics filings at SEC.gov ↗